Boehringer Ingelheim struck a major licensing deal with China’s Sino Biopharmaceutical (SBP Group) covering six pre-clinical cancer programs. The pact includes $358 million in upfront and near-term payments, with milestones potentially reaching $7 billion plus royalties. The transaction represents BI’s continued push into China-led oncology pipelines, and it follows other BI-China collaborations referenced in the report as the companies broaden platform reach. For the industry, the deal adds to the growing pattern of large upfront commitments for early-stage oncology assets, while also highlighting China as a key sourcing region for global partnerships.